用Venetoclax加Azacitidine治疗经脐带血移植后的携带t(16;21)(p11;q22)易位的急性髓系白血病。
Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation.
发表日期：2023 Jul
作者：
Kazuaki Teshima, Sho Ikeda, Ko Abe, Masahiro Yamada, Naoto Takahashi
来源：
Bone & Joint Journal
摘要：
一名62岁女性被确诊患有t(16;21)(p11;q22)的急性髓系白血病（AML）。在诱导治疗后，她取得了完全的血液学缓解，并接受了脐带血干细胞移植（CBT）。在CBT后的第150天，骨髓检查显示复发。我们用维内克洛斯和阿扎胞苷联合治疗拯救患者。在经过五个周期的维内克洛斯和阿扎胞苷治疗后，患者因疾病进展而死亡。鉴于高率的早期复发，即使经过造血干细胞移植，t(16;21)(p11;q22)的AML预后非常差。因此，需要一种新的治疗方法来改善患者的预后。版权所有 © 2023，Teshima et al.
A 62-year-old female was diagnosed with acute myeloid leukemia (AML) with t(16;21)(p11;q22). She achieved complete hematological remission after induction therapy and underwent umbilical cord blood stem cell transplantation (CBT). At 150 days after the CBT, a bone marrow examination revealed relapse. We treated the patient with venetoclax plus azacitidine as salvage therapy. After five cycles of venetoclax and azacitidine therapy, the patient died due to disease progression. The prognosis of AML with t(16;21)(p11;q22) is very poor owing to the high rate of early relapse even after hematopoietic stem cell transplantation. Therefore, a novel therapeutic approach is required to improve patient outcomes.Copyright © 2023, Teshima et al.